# Compass Pathways

Type: Company (CMPS)

Source: GetYourBrief — https://getyourbrief.com/entity/compass-pathways
Canonical HTML page: https://getyourbrief.com/entity/compass-pathways

## Timeline

- **2026-03-25**: King County Resolution — King County Council officially passes the resolution to decriminalize psychedelic mushrooms county-wide.
- **2026**: Anticipated Data Readout — Expected primary endpoint results for the COMP005 Phase 3 trial in TRD.
- **2025-12-31**: Fiscal Year End — Closed 2025 with a strategic focus on regulatory filing preparations.
- **2025-Q3**: Therapist Training Milestone — Completed training for over 500 facilitators to support Phase 3 delivery protocols.
- **2025-Q1**: Phase 3 Expansion — Compass increased the number of active clinical sites for COMP006 to over 50 globally.
- **2023-05-10**: WA SB 5263 Passed — Washington Governor signs a bill to create a psilocybin task force and pilot program.
- **2021-10-04**: Seattle Decriminalization — Seattle City Council passes a resolution to decriminalize the cultivation and possession of psychedelic plants.

## Recent coverage (4 stories, network-wide)

### King County Decriminalizes Psilocybin, Signaling Shift in Psychedelic Policy
2026-03-26 05:07:57 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

King County has officially passed a resolution to decriminalize the possession and use of psychedelic mushrooms, joining a growing list of Pacific Northwest jurisdictions. This move reflects a significant shift toward viewing psilocybin through a public health lens, potentially paving the way for expanded clinical research and therapeutic access in the region.
Full story: https://getbiobrief.com/story/king-county-psilocybin-decriminalization-biotech-impact

### Compass Pathways Reports 2025 Results as Pivotal Phase 3 Data Looms
2026-03-24 15:41:41 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Compass Pathways reported its full-year 2025 financial results, highlighting a strategic focus on its pivotal Phase 3 COMP360 program for treatment-resistant depression. With a cash runway extending into late 2026, the company is positioned for a critical year of clinical readouts and regulatory engagement.
Full story: https://gethealthbrief.com/story/compass-pathways-2025-financial-results-comp360

### Psychedelics Outperform Nicotine Patches in Landmark Smoking Cessation Study
2026-03-17 16:00:29 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2

A new comparative study reveals that psychedelic-assisted therapy significantly exceeds the efficacy of standard nicotine patches for long-term smoking cessation. The findings suggest a paradigm shift in treating nicotine addiction, moving from continuous replacement to episodic, transformative intervention.
Full story: https://getbiobrief.com/story/psychedelics-vs-nicotine-patches-smoking-cessation

### Psilocybin Therapy Shows Unprecedented Efficacy in Smoking Cessation Trials
2026-03-10 16:53:46 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 3

A landmark study has demonstrated that a single dose of psilocybin, paired with psychological support, significantly outperforms traditional nicotine replacement therapies for long-term smoking cessation. The findings suggest a paradigm shift in treating substance use disorders through psychedelic-assisted therapy.
Full story: https://getbiobrief.com/story/psilocybin-smoking-cessation-clinical-trial-results

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.